PDCD1LG2 and acute myeloid leukemia: They found that the expression of immune checkpoints, including PD-L1, PD-L2, MRP1, and MRP2, was remarkably higher in AML patients with lower m6A scores, implying that m6A modification takes part in antileukemia immunity.